DUBLIN, August 30, 2017 /PRNewswire/ --
The "Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022" report has been added to Research and Markets' offering.
The vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 34.30 Billion in 2017, at a CAGR of 7.5%. Factors such as rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the vaccine market.
This report segments the vaccines market into technology, type, disease indication, route of administration, end user, and region. Based on technology, the vaccine market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate vaccines segment is expected to account for the largest share of the global market, in 2017.
Based on the end user, the vaccines market is segmented into pediatrics and adults. The adult segment is expected to register the highest CAGR during the forecast period. Factors like the increasing investments by companies for the development of new adult vaccines and government initiatives for immunization are driving the growth of this segment.
In 2017, North America is expected to dominate the market, followed by Europe. The high growth of the North American market is attributed to the factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines.
While North America is expected to dominate the market in 2017, Asia is expected to register the highest CAGR during the forecast period. The high growth in this market is attributed to increasing investments by companies in the emerging countries of the Asian region such as India and China and rising disposable income.
While the vaccines market presents significant growth opportunities, market growth may be hindered due to the high cost of vaccine development and product recalls. The vaccine market is highly competitive with several big and small players.
- High Prevalence of Infectious Diseases
- Rising Focus on Immunization Programs
- Growing Government Support for Vaccine Development
- Increasing Company Investments Into Vaccine R&D
- High Cost of Vaccine Development
- Product Recalls
- High Growth Prospects in Emerging Markets
- Focus on Therapeutic Vaccines
- Use of Adjuvants in Vaccines
- Inadequate Access to Vaccines
- Vaccine Pricing
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Insights
7 Vaccine Market, By Technology
8 Vaccine Market, By Type
9 Vaccine Market, By Disease Indication
10 Vaccine Market, By Route of Administration
11 Vaccine Market, By End User
12 Vaccine Market, By Region
13 Competitive Landscape
- Abbott Laboratories
- Astellas Pharma Inc.
- Bavarian Nordic
- CSL Limited
- Daiichi Sankyo Company Limited
- Emergent Biosolutions Inc.
- Glaxosmithkline PLC
- Green Cross Corporation
- Incepta Vaccine Ltd.
- Indian Immunologicals Limited
- Johnson & Johnson
- Medimmune LLC
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corporation
- Panacea Biotec
- Paxvax Inc.
- Pfizer Inc.
- Protein Science Corporation
- Pt Bio Farma (Persero)
- Sanofi Pasteur SA
- Serum Institute of India
- Sinovac Biotech Ltd.
- Valneva Se
- Vbi Vaccines Inc.
- Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/research/v2rp44/vaccine_market_by
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets